Short Interest in Standard BioTools Inc. (NASDAQ:LAB) Declines By 18.5%
Short interest in Standard BioTools Inc. (NASDAQ:LAB) decreased by 18.5% in March, totaling 8,281,198 shares as of March 13th. Institutional investors now own about 53.74% of the stock, with several large investors increasing their stakes. The company recently beat revenue and EPS estimates but remains unprofitable, with analysts holding a consensus "Reduce" rating and a target price of $1.35.
OCT 21·GlobeNewswire→
Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 ( GLOBE NEWSWIRE ) -- Standard BioTools Inc. ( NASDAQ: LAB ) today announced that it will publish third quarter 2025 financial results on Tuesday, November 4, 2025, after U.S. market close.
AUG 11·Zacks Commentary→
Standard BioTools ( LAB ) Reports Q2 Loss, Tops Revenue Estimates
Standard BioTools (LAB) delivered earnings and revenue surprises of 0.00% and +5.35%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
